ITPRIPL1 and non-small cell lung carcinoma: ITPRIPL1 may have several advantages over the existing NSCLC biomarkers, such as carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 125, and CYFRA21-1 (Muley et al., 2008; Cedres et al., 2011; Dogan et al., 2014; Chen et al., 2015; Dal Bello et al., 2019).